Anticoagulant/Antiaggregant Use and Postoperative Bleeding Risk in Patients With Bladder Tumor and Benign Prostatic Hyperplasia
Investigation of the Effects of Anticoagulant/Antiaggregant Use on Postoperative Bleeding Risk in Patients Operated for Bladder Tumor and Benign Prostatic Hyperplasia
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Abdullah Ilktac, MD
- Phone Number: +905352894863
- Email: ailktac@bezmialem.edu.tr
Study Contact Backup
- Name: Cevper Ersoz, MD
- Phone Number: +905325823291
- Email: cersoz@bezmialem.edu.tr
Study Locations
-
-
-
Istanbul, Turkey, 34093
- Bezmialem Vakif University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients undergoing complete endoscopic transurethral tumor resection (TUR-BT) for bladder cancer
- Patients undergoing TURP due to benign prostatic hyperplasia
- Patients undergoing open prostatectomy due to benign prostatic hyperplasia
Exclusion Criteria:
- Patients who underwent incomplete transurethral tumor resection for bladder cancer
- Patient who underwent TUR biopsy for restaging with no obvious macroscopic tumoral lesion
- Patients who underwent cystectomy for bladder cancer
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
TURP patients using anticoagulant/antiaggregant medication
Patients who used anticoagulant/antiaggregant medication for any reason (eg: coronary artery disease, atrial fibrillation, cerebrovascular disease) before surgery and underwent endoscopic prostatectomy (TURP).
|
|
TURP patients not using anticoagulant/antiaggregant medication
Patients with no history of anticoagulant/antiaggregant medication and underwent endoscopic prostatectomy (TURP).
|
|
TUR-BT patients using anticoagulant/antiaggregant medication
Patients who used anticoagulant/antiaggregant medication for any reason (eg: coronary artery disease, atrial fibrillation, cerebrovascular disease) before surgery and underwent endoscopic bladder tumor resection (TUR-BT).
|
|
TUR-BT patients not using anticoagulant/antiaggregant medication
Patients with no history of anticoagulant/antiaggregant medication and underwent endoscopic bladder tumor resection (TUR-BT).
|
|
Open prostatectomy patients using anticoagulant/antiaggregant medication
Patients who used anticoagulant/antiaggregant medication for any reason (eg: coronary artery disease, atrial fibrillation, cerebrovascular disease) before surgery and underwent open prostatectomy (OP).
|
|
Open prostatectomy patients not using anticoagulant/antiaggregant medication
Patients with no history of anticoagulant/antiaggregant medication and underwent open prostatectomy (OP).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Episode of clot retention
Time Frame: Immediately after the surgery up to 1 month
|
Presence of clot retention due to hematuria after the operation which requires manuel irrigation
|
Immediately after the surgery up to 1 month
|
|
Requirement of blood transfusion
Time Frame: Immediately after the surgery up to 1 month
|
Gross hematuria requiring blood transfusion
|
Immediately after the surgery up to 1 month
|
|
Re-operation rates
Time Frame: Immediately after the surgery up to 1 month
|
Re-operation requirement for hematuria
|
Immediately after the surgery up to 1 month
|
|
Duration of hospitalization
Time Frame: Immediately after the surgery up to discharge
|
Duration of hospitalization
|
Immediately after the surgery up to discharge
|
|
Rate of re-admission
Time Frame: From discharge up to one month
|
Rate of re-admission due to hematuria
|
From discharge up to one month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative hematocrit/hemoglobin levels
Time Frame: Immediately after the surgery up to discharge
|
Change in the Postoperative hematocrit/hemoglobin levels compared to the preoperative values.
|
Immediately after the surgery up to discharge
|
|
Amount of irrigation volume
Time Frame: Immediately after the surgery up to discharge
|
Amount of postoperative continuous bladder irrigation volume
|
Immediately after the surgery up to discharge
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Abdullah Ilktac, MD, Bezmialem Vakif University, Faculty of Medicine, Department of Urology
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Urinary Bladder Diseases
- Postoperative Complications
- Hematologic Diseases
- Prostatic Diseases
- Urination Disorders
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Hemorrhage
- Prostatic Hyperplasia
- Hyperplasia
- Urinary Bladder Neoplasms
- Urinary Retention
- Postoperative Hemorrhage
- Transfusion Reaction
- Hematuria
Other Study ID Numbers
Other Study ID Numbers
- 196083
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.